Letter to shareholders - Januray 2020. pdfRead

Sensorion presents new SENS-401 preclinical data at ARO MidWinter Meeting 2020. pdfRead

Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference. pdfRead

Sensorion Announces Positive Data Safety Monitoring Board Review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss. Read

Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss. French ministry of armed forces to participate in the study. Read


20191220 pipeline


Patient center

Corporate presentation

Next events